AACR 2022 | CAR-T cell approaches to combat an immunosuppressive tumor microenvironment

Yufei Wang, PhD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of how studies are using different checkpoint inhibitor blockades for CAR-T cell therapies. For example, utilising anti-VEGFR to destroy tumor vasculature and combat an immunosuppressive tumor microenvironment. This interview took place at the American Association for Cancer Research (AACR) 2022 Annual Meeting in New Orleans, LA.